Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Yann Echelard
Advertisement
Yann Echelard, PhD is vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Yann Echelard
Advertisement
Latest Updated Articles
Advertisement
Advertisement